We are live on ! Find out more
ABUS icon

Arbutus Biopharma
ABUS

62 hedge funds and large institutions have $44M invested in Arbutus Biopharma in 2019 Q2 according to their latest regulatory filings, with 18 funds opening new positions, 16 increasing their positions, 17 reducing their positions, and 25 closing their positions.

New
Increased
Maintained
Reduced
Closed

6% less repeat investments, than reductions

Existing positions increased: 16 | Existing positions reduced: 17

5.82% less ownership

Funds ownership: 42.96% → 37.14% (-5.8%)

14% less funds holding

Funds holding: 72 → 62 (-10)

28% less first-time investments, than exits

New positions opened: 18 | Existing positions closed: 25

49% less call options, than puts

Call options by funds: $25K | Put options by funds: $49K

49% less capital invested

Capital invested by funds: $86.5M → $44M (-$42.5M)

Holders
62
Holders Change
-10
Holders Change %
-13.89%
% of All Funds
1.35%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
18
Increased
16
Reduced
17
Closed
25
Calls
$25K
Puts
$49K
Net Calls
-$24K
Net Calls Change
-$443K

Top Buyers

1
Morgan Stanley
Morgan Stanley
New York
+$1.65M
2
Jennison Associates
Jennison Associates
New York
+$1.61M
3
Millennium Management
Millennium Management
New York
+$1.33M
4
SFM
Sphera Funds Management
Israel
+$1.28M
5
Hudson Bay Capital Management
Hudson Bay Capital Management
Connecticut
+$601K

Top Sellers

1
EC
EcoR1 Capital
California
-$7.78M
2
BlackRock
BlackRock
New York
-$4.23M
3
State Street
State Street
Massachusetts
-$1.36M
4
JP Morgan Chase
JP Morgan Chase
New York
-$1.21M
5
DCM
DAFNA Capital Management
California
-$884K
Name Holding Trade Value Shares
Change 		Change in
Stake
MAM
51
Meeder Asset Management
Ohio
$2K +$504 +197 +30%
FDCDDQ
52
Federation des caisses Desjardins du Quebec
Quebec, Canada
$1.66K – – –
Daiwa Securities Group
53
Daiwa Securities Group
Japan
$1K – – –
TF
54
TimeScale Financial
Massachusetts
$1K +$767 +300 New
PCP
55
Proficio Capital Partners
Massachusetts
$1K +$1.27K +495 New
Simplex Trading
56
Simplex Trading
Illinois
$1K +$1.72K +671 New
SQA
57
Simon Quick Advisors
New Jersey
$208 +$256 +100 New
EC
58
EcoR1 Capital
California
– -$7.78M -2,172,883 Closed
DCM
59
DAFNA Capital Management
California
– -$884K -246,900 Closed
B
60
Bailard
California
– -$816K -228,000 Closed
AA
61
ALPS Advisors
Colorado
– -$480K -134,053 Closed
CS
62
Candriam SCA
Luxembourg
– -$376K -105,000 Closed
Bank of New York Mellon
63
Bank of New York Mellon
New York
– -$350K -97,968 Closed
OAM
64
Oxford Asset Management
United Kingdom
– -$256K -71,560 Closed
Charles Schwab
65
Charles Schwab
California
– -$236K -65,900 Closed
California State Teachers Retirement System (CalSTRS)
66
California State Teachers Retirement System (CalSTRS)
California
– -$196K -54,700 Closed
RhumbLine Advisers
67
RhumbLine Advisers
Massachusetts
– -$174K -48,597 Closed
State of Wisconsin Investment Board
68
State of Wisconsin Investment Board
Wisconsin
– -$169K -47,300 Closed
PP
69
PDT Partners
New York
– -$108K -30,200 Closed
AQR Capital Management
70
AQR Capital Management
Connecticut
– -$101K -28,128 Closed
Manulife (Manufacturers Life Insurance)
71
Manulife (Manufacturers Life Insurance)
Ontario, Canada
– -$93K -26,188 Closed
New York State Common Retirement Fund
72
New York State Common Retirement Fund
New York
– -$88K -24,500 Closed
AIG
73
American International Group
New York
– -$81K -22,516 Closed
SAM
74
Seelaus Asset Management
New Jersey
– -$51K -14,300 Closed
VOYA Investment Management
75
VOYA Investment Management
Georgia
– -$48K -13,404 Closed
1 2
3
4

ABUS Hedge Fund Activity: Q2 2019 in Review

62 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in Arbutus Biopharma (ABUS) for Q2 2019, worth a combined $44M — down 49% from $86.5M a quarter earlier.

Sellers outnumbered buyers: 25 funds closed out of ABUS and 18 opened new positions — a net loss of 7 holders — while 17 trimmed existing stakes and 16 added.

The largest buyer was Morgan Stanley, adding an estimated $1.65M. The largest seller was EcoR1 Capital, exiting entirely with an estimated $7.78M sold.

  • 62 institutional investors held Arbutus Biopharma (ABUS) as of Q2 2019, down from 72 in Q1 2019.
  • Funds reported $44M of Arbutus Biopharma stock for Q2 2019, down 49% quarter-over-quarter.
  • 18 funds opened new Arbutus Biopharma positions in Q2 2019 and 25 closed out, a net change of -7 holders.
  • The largest Arbutus Biopharma buyer in Q2 2019 was Morgan Stanley, an estimated $1.65M added.
  • The largest Arbutus Biopharma seller in Q2 2019 was EcoR1 Capital, an estimated $7.78M sold.

Based on aggregated 13F filings for Q2 2019.